Normally, glaucoma can be treated with medication or laser surgery; however, some cases are not responsive to these treatments. That is where Optonol’s patented Ex-PRESS Miniature Glaucoma Implant comes in. The treatment significantly reduces intra-ocular pressure, by ridding the eye of excess fluid, which does not drain normally in glaucoma sufferers. The device can also serve as an effective, long-term alternative to the traditional treatments.
As reported by Israel21c.org, “[L]ast year, American optical giant Ciba Vision acquired the rights to market it in the United States and Canada. Since its introduction on the American market last year, there have been hundreds of cases implanted, and almost 800 doctors are now certified to use the device, according to Andrea Argenbright of Ciba.” Ex-PRESS has been approved by the US Food and Drug Administration, as well as by the CE authorities for marketing in Europe.
Located in Neve Ilan, a high-tech industrial park just off the main highway between Jerusalem and Tel Aviv, Optonol Ltd. is an advanced technology company founded in 1996 by a group of experienced medical practitioners, engineers and entrepreneurs.
As reported by Israel21c.org, “[L]ast year, American optical giant Ciba Vision acquired the rights to market it in the United States and Canada. Since its introduction on the American market last year, there have been hundreds of cases implanted, and almost 800 doctors are now certified to use the device, according to Andrea Argenbright of Ciba.” Ex-PRESS has been approved by the US Food and Drug Administration, as well as by the CE authorities for marketing in Europe.
Located in Neve Ilan, a high-tech industrial park just off the main highway between Jerusalem and Tel Aviv, Optonol Ltd. is an advanced technology company founded in 1996 by a group of experienced medical practitioners, engineers and entrepreneurs.